Most Popular News Stories on OBR Daily
The ten most read articles from OBR daily in the past two weeks, updated continually:
#1: New Cancer Drugs: Affordable by the 1 Percent?
(The Fiscal Times) Jan 23, 2012 - Julie Grabow, an oncologist at the Fred Hutchinson Cancer Center in Seattle, recently prescribed an exciting new therapy for a 60-year-old woman with metastatic breast cancer.
read article »
#2: Cell Therapeutics Pulls Cancer Drug After CEO Boasted About Approval Chances
(The Street) Jan 30, 2012 - Cell Therapeutics withdrew its U.S. approval application for the experimental lymphoma pixantrone due to unresolved and undisclosed "communications" with the U.S. Food and Drug Administration, the company said.
read article »
#3: 2 Biotech Firms Bolster Their Drug Pipelines Through Deals
(NYT/Dealbook) Jan 26, 2012 - Two big biotechnology companies announced on Thursday that they would buy smaller companies that are harnessing novel technologies to develop drug treatments for leukemias and lymphomas.
read article »
#4: FDA Approves Inlyta to Treat Patients With a Type of Advanced Kidney Cancer
(FDA) Jan 27, 2012 - The U.S. Food and Drug Administration today approved Inlyta (axitinib) to treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer.
read press release »
#5: FDA Chides Celgene, Novartis on Drug Promotion
(Reuters) Jan 25, 2012 - Health regulators said drugmakers Celgene Corp and Novartis AG misrepresented their cancer drugs to doctors, overstating how well the medicines targeted tumors without having evidence to support it.
read article »
#6: AB Soars 72% as Cancer Drug Beats Pfizer’s Sutent: Paris Mover
(Bloomberg) Feb 2, 2012 - AB Science SA soared 72 percent after a clinical trial showed the company’s experimental cancer drug masitinib worked better than a Pfizer Inc. medicine on gastrointestinal tumors.
read article »
#7: US FDA Approves Roche and Curis Skin Cancer Drug
(Fox Business/Dow Jones Newswires) Jan 30, 2012 - The U.S. Food and Drug Administration approved a drug developed by Roche Holding AG and Curis Inc. to treat advanced cases of basal cell skin cancer, the most common type of skin cancer.
read article »
#8: More Evidence for Oxaliplatin as Colon Cancer Chemotherapy
(U.S. News & World Report/HealthDay News) Jan 20, 2012 - Adding oxaliplatin to a standard chemotherapy regimen boosts survival rates for patients with advanced colon cancer, according to a new study that bolsters previous research on the drug by looking at a broader group of patients.
read article »
#9: Why CEO Replacement Is Good News For Dendreon
(Forbes) Feb 1, 2012 - The news that Dendreon is under new management should cheer investors and help lay the groundwork for figuring out how to best sell the company’s groundbreaking prostate cancer treatment, Provenge, which aims to harness the immune system to fight tumors.
read article »
#10: Takeda Wins Approval for New Way to Inject Velcade Cancer Drug
(Bloomberg Businessweek) Jan 24, 2012 - Takeda Pharmaceutical Co., Asia’s biggest drugmaker, won U.S. approval to administer its cancer medicine Velcade under the skin, a form of injection that causes fewer patients to experience the drug’s side effects.
read article »